
Tidak ada bukti kredibel bahwa Sam Altman, CEO OpenAI sejak 2019, menggunakan metformin.
Klaim ini tidak memiliki dasar dalam catatan publik, pengungkapan kesehatan, atau pelaporan terverifikasi.
Informasi kesehatan Altman tetap bersifat pribadi.
Altman's documented activities center on OpenAI's product roadmap. Recent initiatives include OpenAI Dots, his unveiled ChatGPT AI personal agent, alongside the 2026 DevDay announcements. His tracked signals show 94 connections to Artificial Intelligence developments.
Health rumors about prominent figures often circulate online without verification. Without direct statements from Altman or credible medical sources, claims about his medications should be treated as unsubstantiated speculation rather than fact.